Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel.
Paiva B, Manrique I, Rytlewski J, Campbell T, Kazanecki CC, Martin N, Anderson LD Jr, Berdeja JG, Lonial S, Raje NS, Lin Y, Moreau P, San-Miguel JF, Munshi NC, Kaiser SM.
Paiva B, et al.
Blood Cancer Discov. 2023 Sep 1;4(5):365-373. doi: 10.1158/2643-3230.BCD-23-0044.
Blood Cancer Discov. 2023.
PMID: 37486974
Free PMC article.